In 2020, the U.S. Food and Drug Administration (FDA) asked manufacturers to remove Zantac from the market. The drugmakers have consistently maintained that there is no evidence Zantac exposed users to harmful levels of NDMA.
Scope of Pending Litigation
Judge Medinilla is overseeing the majority of nearly 80,000 cases pending in the United States. In addition to the Delaware cases, approximately 4,000 claims are pending in California state court, with another 2,000 in various state courts nationwide.
Delaware judge lets more than 70,000 Zantac lawsuits go forward : Previous Legal Outcomes
The legal landscape for Zantac litigation has been mixed. Last month, a jury in Chicago ruled in favor of GSK and Boehringer Ingelheim, rejecting an Illinois woman’s claim that Zantac caused her colon cancer. In 2022, another judge dismissed around 50,000 lawsuits consolidated in federal court in Florida, ruling that the plaintiffs’ expert witnesses did not provide sound scientific support for their claims. Plaintiffs are appealing that decision, which involves different experts from those in the Delaware case.
